Coronavirus may have spread to humans as early as October 2019 – study – The Jerusalem Post

A genetic study of samples from more than 7,500 people infected with COVID-19 suggests the new coronavirus spread quickly around the world after it emerged in China sometime between October and December last year, scientists said on Wednesday.

Scientists at University College London's Genetics Institute found almost 200 recurrent genetic mutations of the new coronavirus - SARS-CoV-2 - which the UCL researchers said showed how it is adapting to its human hosts as it spreads.

"Phylogenetic estimates support that the COVID-2 pandemic started sometime around Oct. 6, 2019 to Dec. 11, 2019, which corresponds to the time of the host jump into humans," the research team, co-led by Francois Balloux, wrote in a study published in the journal Infection, Genetics and Evolution.

Balloux said the analysis also found that the virus was and is mutating, as normally happens with viruses, and that a large proportion of the global genetic diversity of the virus causing COVID-19 was found in all of the hardest-hit countries.

That suggests SARS-CoV-2 was being transmitted extensively around the world from early on in the epidemic, he said.

"All viruses naturally mutate. Mutations in themselves are not a bad thing and there is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected," he said. "So far, we cannot say whether SARS-CoV-2 is becoming more or less lethal and contagious."

In a second study also published on Wednesday, scientists at Britain's University of Glasgow who also analyzed SARS-CoV-2 virus samples said their findings showed that previous work suggesting there were two different strains was inaccurate.

JUST ONE VIRUS TYPE CIRCULATING

A preliminary study by Chinese scientists in March had suggested there may have been two strains of the new coronavirus causing infections there, with more of them more "aggressive" than the other.

But, publishing their analysis in the journal Virus Evolution, the Glasgow team said only one type of the virus was circulating.

More than 3.71 million people have been reported to be infected by the novel coronavirus globally and 258,186 have died, according to a Reuters tally.

Cases have been reported in more than 210 countries and territories since they were first identified in China in December 2019.

The genetic studies offer "fascinating" insights into the evolution of the virus, and emphasize that it is "a moving target with an unknown evolutionary destination," said Jonathan Stoye, head of the division of virology at Britain's Francis Crick Institute.

"All the evidence is entirely consistent with an origin towards the end of last year, and there's no reason to question that in any way," Stoye said.

The World Health Organization said the French case was "not surprising" and urged countries to investigate any other early suspicious cases.

Balloux's team screened the genomes of more than 7,500 viruses from infected patients around the world. Their results add to a growing body of evidence that SARS-CoV-2 viruses share a common ancestor from late 2019, suggesting this was when the virus jumped from a previous animal host into people.

Link:

Coronavirus may have spread to humans as early as October 2019 - study - The Jerusalem Post

Team reveals genomic history of ancient civilizations in the Andes – UC Santa Cruz

An international research team has conducted the first in-depth, wide-scale study of the genomic history of ancient civilizations in the central Andes mountains and coast before European contact.

The findings, published online May 7 in Cell, reveal early genetic distinctions between groups in nearby regions, population mixing within and beyond the Andes, surprising genetic continuity amid cultural upheaval, and ancestral cosmopolitanism among some of the region's most well-known ancient civilizations.

Led by researchers at Harvard Medical School and the University of California, Santa Cruz, the team analyzed genome-wide data from 89 individuals who lived between 500 and 9,000 years ago. Of these, 64 genomes, ranging from 500 to 4,500 years old, were newly sequencedmore than doubling the number of ancient individuals with genome-wide data from South America.

The analysis included representatives of iconic civilizations in the Andes from whom no genome-wide data had been reported before, including the Moche, Nasca, Wari, Tiwanaku and Inca.

"This was a fascinating and unique project," said Nathan Nakatsuka, first author of the paper and an MD/PhD student in the lab of David Reich in the Blavatnik Institute at HMS.

"It represents the first detailed study of Andean population history informed by pre-Colonial genomes with wide-ranging temporal and geographic coverage," said Lars Fehren-Schmitz, associate professor at UC Santa Cruz and co-senior author of the paper with Reich.

"This study also takes a major step toward redressing the global imbalance in ancient DNA data," said Reich, professor of genetics at HMS and associate member of the Broad Institute of MIT and Harvard.

"The great majority of published ancient DNA studies to date have focused on western Eurasia," he said. "This study in South America allows us to begin to discern at high resolution the detailed history of human movements in this extraordinarily important part of the world."

Attention on the Andes

The central Andes, surrounding present-day Peru, is one of the few places in the world where farming was invented rather than being adopted from elsewhere and where the earliest presence of complex civilizations in South America has been documented so far. While the region has been a major focus of archaeological research, there had been no systematic characterization with genome-wide ancient DNA until now, the authors said.

Geneticists, including several of the current team members, previously studied the deep genetic history of South America as a whole, including analysis of several individuals from the Andean highlands from many thousands of years ago. There have also been analyses of present-day residents of the Andes and a limited number of mitochondrial or Y-chromosome DNA analyses from individual ancient Andean sites.

The new study, however, expands on these findings to provide a far more comprehensive portrait. Now, Nakatsuka said, researchers are "finally able to see how the genetic structure of the Andes evolved over time."

By focusing on what is often called pre-Columbian history, the study demonstrates how large ancient DNA studies can reveal more about ancient cultures than studying present-day groups alone, said Reich.

"In the Andes, reconstruction of population history based on DNA analysis of present-day people has been challenging because there has so been much demographic change since contact with Europeans," Reich explained. "With ancient DNA data, we can carry out a detailed reconstruction of movements of people and how those relate to changes known from the archaeological record."

'Extraordinary' ancient population structure

The analyses revealed that by 9,000 years ago, groups living in the Andean highlands became genetically distinct from those that eventually came to live along the Pacific coast. The effects of this early differentiation are still seen today.

The genetic fingerprints distinguishing people living in the highlands from those in nearby regions are "remarkably ancient," said Nakatsuka, who will receive his PhD in systems, synthetic and quantitative biology in May.

"It is extraordinary, given the small geographic distance," added Reich.

By 5,800 years ago, the population of the north also developed distinct genetic signatures from populations that became prevalent in the south, the team found. Again, these differences can be observed today.

After that time, gene flow occurred among all regions in the Andes, although it dramatically slowed after 2,000 years ago, the team found.

"It is exciting that we were actually able to determine relatively fine-grained population structure in the Andes, allowing us to differentiate between coastal, northern, southern and highland groups as well as individuals living in the Titicaca Basin," said Fehren-Schmitz.

"This is significant for the archaeology of the Andes and will now allow us to ask more specific questions with regards to local demographies and cultural networks," said study co-author Jose Capriles of Pennsylvania State University.

Genetic intermingling

The team discovered genetic exchanges both within the Andes and between Andean and non-Andean populations.

Ancient people moved between south Peru and the Argentine plains and between the north Peru coast and the Amazon, largely bypassing the highlands, the researchers found.

Fehren-Schmitz was especially interested to uncover signs of long-range mobility in the Inca period. Specifically, he was surprised to detect ancient North Coast ancestry not only around Cusco, Peru, but also in a child sacrifice from the Argentinian southern Andes.

"This could be seen as genetic evidence for relocations of individuals under Inca rule, a practice we know of from ethnohistorical, historical and archaeological sources," he said.

Although the findings of genetic intermingling throughout the Andes correlate with known archaeological connections, they will likely prompt additional archaeological research to understand the cultural contexts underlying the migrations, said Nakatsuka.

"Now we have more evidence demonstrating important migrations and some constraints on when they happened, but further work needs to be done to know why exactly these migrations occurred," he said.

Long-term continuity

The analyses revealed that multiple regions maintained genetic continuity over the past 2,000 years despite clear cultural transformations.

The finding contrasts with many other world regions, where ancient DNA studies often document substantial genetic turnover during this period, said Reich.

The population structures that arose early on persisted through major social changes and on into modern societies, the authors said. The discoveries offer new evidence that can be incorporated alongside archaeological and other records to inform theories on the ancient history of different groups in the region.

"To our surprise, we observed strong genetic continuity during the rise and fall of many of the large-scale Andean cultures, such as the Moche, Wari and Nasca," said Nakatsuka. "Our results suggest that the fall of these cultures was not due to massive migration into the region, e.g., from an invading military force, a scenario which had been documented in some other regions of the world."

Two exceptions to the continuity trend were the vast urban centers that the Tiwanaku and Inca cultures called home. Rather than being fairly genetically homogeneous, the capital regions of these civilizations were cosmopolitan, hosting people from many genetic backgrounds, the team found.

"It was interesting to start to see these glimpses of ancestral heterogeneity," said Nakatsuka. "These regions have some similarity to what we see now in places like New York City and other major cities where people of very different ancestries are living side by side."

Cooperative authorship

The study included authors from many disciplines and many countries, including Argentina, Australia, Bolivia, Chile, Germany, Peru, the United Kingdom and the United States.

"This is an impressive interdisciplinary but, just as importantly, international collaboration," said study co-author Bastien Llamas of the University of Adelaide. "All worked very closely to draft this manuscript under the leadership of Fehren-Schmitz and Reich."

It was important to team up with local scientists who belong to communities that descend from the individuals analyzed in the study, Fehren-Schmitz said, and to obtain permission from and continually engage with indigenous and other local groups as well as local governments.

The analysis of DNA from ancient individuals can have significant implications for present-day communities. One concerns the physical handling of the skeletal materials, which might be sensitive to the groups involved.

The work provided opportunities to heal past wounds. In one case, a sample from Cusco, previously housed in the U.S., was repatriated to Peru. Other remains that had long ago been taken improperly from burial sites were able to be carbon-dated and reburied.

In the absence of pre-Columbian written histories, archaeology has been the main source of information available to reconstruct the complex history of the continent, said study co-author Chiara Barbieri of the University of Zurich.

With the study of ancient DNA, we can read the demographic history of ancient groups and understand how ancient and present-day groups are related, she said. The link with the genetic study of living populations opens a direct dialogue with the past and an occasion to involve local communities.

The researchers sought to deeply involve communities with the help of archaeologists from each area, said Nakatsuka. Their efforts included giving public talks about the study and translating materials into Spanish.

"We were really happy to have the summary and key findings of our paper translated and included as part of the Cell paper itself, to increase accessibility of our work," said Nakatsuka. "We hope future studies will do similar translations, including versions suitable for lay audiences for schools, museum exhibits and cultural organizations, which we are in the process of doing as well."

Original post:

Team reveals genomic history of ancient civilizations in the Andes - UC Santa Cruz

Regeneron Reports First Quarter 2020 Financial and Operating Results – BioSpace

TARRYTOWN, N.Y., May 5, 2020 /PRNewswire/ --

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2020 and provided a business update.

"Over 30 years, the Regeneron team has built a science and technology engine uniquely suited to address the COVID-19 pandemic and we are applying our signature passion, innovation, and drive to advance solutions. Our novel antibody cocktail, REGN-COV2, which is specifically-designed for both prevention and treatment, is expected to begin human studies in June and we are working in parallel to have large-scale quantities available by late summer," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "Beyond our COVID-19 efforts, we maintain our commitment to the many other patients with serious diseases who are counting on us. In the first quarter, we saw continued growth with EYLEA, Dupixent, and Libtayo in the U.S. driven by underlying demand despite the impact of the pandemic. Moreover, we continue to advance our broad immuno-oncology platform, including the PD-1 inhibitor Libtayo, for which we plan regulatory submissions this year in both non-small cell lung cancer and basal cell carcinoma, based on recent promising late-stage results."

"We believe our recent revision to the accounting presentation better reflects the nature of revenues earned and costs incurred and simplifies our financial reporting," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "We were also pleased to close the Praluent restructuring transaction with Sanofi, which we expect to be accretive beginning in the second quarter of 2020."

Financial Highlights

($ in millions, except per share data)

Q1 2020

Q1 2019

% Change

Total revenues(4)

$

1,828

$

1,373

33

%

GAAP net income

$

625

$

461

36

%

GAAP net income per share - diluted

$

5.43

$

3.99

36

%

Non-GAAP net income(1)

$

771

$

518

49

%

Non-GAAP net income per share - diluted(1)

$

6.60

$

4.45

48

%

Business Highlights

Key Pipeline Progress

Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:

EYLEA (aflibercept) Injection

Dupixent (dupilumab)

Oncology Program

Praluent (alirocumab)

Evinacumab, an antibody to ANGPTL3

Pozelimab, an antibody to C5

REGN-EB3, a multi-antibody therapy to Ebola virus infection

COVID-19 Update

Business Development Update

In December 2019, the Company and Sanofi also announced their intent to restructure their antibody collaboration for Kevzara. The companies continue to assess potential terms of this restructuring in light of the recently launched clinical programs evaluating Kevzara in patients hospitalized with COVID-19.

First Quarter 2020 Financial Results

Effective January 1, 2020, Regeneron has implemented changes in the presentation of its financial statements related to certain reimbursements and other payments for products developed and commercialized with collaborators. The Company made these changes in presentation to better reflect the nature of the Company's costs incurred and revenues earned pursuant to arrangements with collaborators and to enhance the comparability of Regeneron's financial statements with industry peers. The change in presentation has been applied retrospectively. See Note (4) below for further information.

Revenues

Total revenues increased by 33% to $1.828 billion in the first quarter of 2020, compared to $1.373 billion in the first quarter of 2019.

EYLEA net product sales in the United States were $1.172 billion in the first quarter of 2020, compared to $1.074 billion in the first quarter of 2019. Overall distributor inventory levels for EYLEA in the United States remained within the Company's one-to-two-week targeted range.

Total revenues also include Sanofi and Bayer collaboration revenues(2) of $528 million in the first quarter of 2020, compared to $246 million in the first quarter of 2019. Sanofi collaboration revenue in the first quarter of 2020 included the Company's share of profits from collaboration antibodies (Dupixent, Praluent, and Kevzara) of $171 million, while Sanofi collaboration revenue in the first quarter of 2019 included the Company's share of losses from collaboration antibodies of ($28) million. The change in the Company's share of profits (losses) from collaboration antibodies was primarily driven by higher Dupixent profits.

Refer to Table 4 for a summary of collaboration revenue.

Operating Expenses

GAAP

%Change

Non-GAAP(1)

%Change

($ in millions)

Q1 2020

Q1 2019

Q1 2020

Q1 2019

Research and development (R&D)

$

584

$

486

20

%

$

527

$

427

23

%

Selling, general, and administrative (SG&A)

$

367

$

291

26

%

$

307

$

242

27

%

Original post:

Regeneron Reports First Quarter 2020 Financial and Operating Results - BioSpace

Scientists at Ben-Gurion University of the Negev Develop Anti-Coronavirus Surface Coating Based on Nanomate… – The Auto Channel

BEER-SHEVA, Israel, May 5, 2020 -- The coronavirus, SARS-CoV-2, which is responsible for the current COVID-19 pandemic, is transmitted between people mainly via respiratory droplets, but it is known that the virus remains stable on various surfaces for days. One of the first indications for this came from the Diamond Princess cruise ship, where active virus particles were found even 17 days after the ship was evacuated. In light of the possibility that the virus can spread through contaminated surfaces, it is important to be able to sterilize surfaces with high contamination potential, such as doorknobs, elevator buttons or handrails in public areas in general, and in hospitals and clinics in particular. However, current disinfectants are mainly based on chemicals such as poisonous sodium hypochlorite (bleach) or alcohol, both of which provide only a temporary measure until the next exposure to the virus.

Certain metals can be lethal, even in small quantities, for viruses and bacteria and are not poisonous to humans. In proof of concept experiments, in which also PhD students Yariv Greenshpan and Esti Toledo, and postdoc Guillaume Le Saux participated, the researchers assessed the effect of surfaces coated with nanoparticles of various metals on the infectivity of lentiviruses, which belong to the HIV family, in human cells. Findings show that surfaces coated with copper nanoparticles strongly block infection of the cells by the virus. These ongoing experiments show a huge potential for copper ions in preventing surface-mediated infection with SARS-CoV-2.

Based on these findings, the researchers are developing anti-viral coatings that can be painted or sprayed on surfaces. The coatings are based on polymers, which are the starting materials of plastics and paints, and contain nanoparticles of copper and other metals. The nanoparticles embedded in the polymer will enable controlled release of metal ions onto the coated surface. Studies show that these ions have a strong anti-viral effect, which can eradicate virus particles that adhere to the surface. Because the release of ions is extremely slow, the coating can be effective for a long period of time weeks and even months, and it will reduce the infectivity of the virus particles by more than 10-fold.

Josh Peleg, CEO, BGN Technologies, said, "The need to develop anti-viral coatings has greatly increased recently, with the SARS-CoV-2outbreak, and this need will likely remain high even after the pandemic ends, due to increased awareness. In addition, the product will be efficient as a general anti-viral and anti-bacterial coating. It can be applicable for medical settings, as an anti-pathogenic substance in places with increased risk of contamination, such as hospitals, but also for home use, and in public spaces such as schools, airports, public transportation and cinemas. We see a widespread and multidisciplinary academic commitment for finding solutions to currently medical and financial challenges as well as to the challenge of returning to normalcy once the pandemic wanes."

The research activity of Prof. Porgador and Dr. Schvartzman is part of the coronavirus research task force, founded by Prof. Daniel Chamovitz, President of BGU. To support this activity, it was decided to divert research funds in order to find rapid solutions for various challenges associated with the coronavirus pandemic. This invention received the support of the Israel Innovation Authority, in response to a call for proposals for coping with the coronavirus. The project is one of 27 proposals submitted to the Israel Innovation Authority by BGN Technologies, the technology transfer company of BGU, based on innovative and diverse inventions of researchers at BGU and the National InstituteforBiotechnologyin theNegev(NIBN) for the prevention, diagnosis and treatment of COVID-19.

Prof. Angel Porgador said, "The current coronavirus is transmitted not only through droplet spray but also via various surfaces that can convey the virus from one person to another. Furthermore, research shows that the virus remains viable on various surfaces for extended periods of time, of days and even longer. Therefore, there is a clear need for durable anti-viral coatings that can be sprayed or painted on surfaces, just like paint or varnish, and that will prevent viral transmission. These surfaces can include handles, buttons, railways or any other public surface that poses increased danger, in particular in places with a high concentration of potential carriers, such as hospitals or clinics. It is important to remember that we are developing coatings that will be effective not only against the coronavirus but also against other viruses, as indicated in our proof of concept experiments, and also against bacteria, so they will be relevant for a wide range of applications."

Dr. Mark Schvartzman commented, "While current surface disinfection methods rely mostly on substances that are poisonous for people, such as bleach, or on substances that evaporate readily being based on alcohol, the coating that we are developing is based on metals that are toxic for viruses or bacteria, but completely human friendly. It should be noted that until now using such metals for anti-viral applications has encountered significant challenges due to the nature of the metals, such as the tendency to oxidize and corrode. Nanoparticles provide a solution to these obstacles. Another advantage of nanoparticles is the large surface area to volume ratio, which results in an efficient anti-viral surface area using a relatively small amount of metal. Additionally, nanoparticles of anti-viral metal can be easily embedded in a polymer that can coat the relevant surfaces for extended periods of time."

About BGN Technologies

BGN Technologiesis the technology companyof Ben-Gurion University, Israel. The company brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students. To date, BGNTechnologieshas established over 100 startup companiesin the fields of biotech, hi-tech, and cleantech as well as initiating leading technology hubs,incubators, and accelerators.Over the past decade, it has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, IBM, PayPal, Cincinnati Children's Medical Center, Merck, Sigma and Bayer, securing value and growth for Ben-Gurion University as well as for the Negev region.For more information, visit the BGN Technologies website.

About NIBN

The National Institute for Biotechnology in the Negev Ltd. (NIBN), a unique research institute located within Ben-Gurion University of the Negev (BGU), is the first self-organized, independent research entity established under the auspices of a university in Israel.

The NIBN was established as a company in November 2009 through a trilateral agreement between the Israeli Government, Mr. Edgar de Picciotto, and Ben-Gurion University.

The mission of the NIBN is to conduct multi-disciplinary applied research guided by a clear biotechnology vision, to bridge the gap between basic and applied innovative research, and facilitate the commercialization of novel ideas and technologies developed by NIBN researchers.

Research at the NIBN is focused in several key areas: cancer, infectious diseases, autoimmune and metabolic diseases, human genetic disorders, neurodegenerative diseases, and applied biotechnology, including AgBio. The decision to focus on these topics combines existing strengths and resources unique to the NIBN and BGU. For more information, visit theNIBN website

Media Contact:

Tsipi HaitovskyGlobal Media LiaisonBGN TechnologiesTel: +972-52-598-9892E-mail: [emailprotected]

SOURCE BGN Technologies

Here is the original post:

Scientists at Ben-Gurion University of the Negev Develop Anti-Coronavirus Surface Coating Based on Nanomate... - The Auto Channel

COVID-19 and food security – Fitzwilliam College, University of Cambridge

This article is a commentary by Fitzwilliam Honorary Fellow ProfessorM S SwaminathanFRS (PhD Botany 1950), as told to his daughter Nitya Rao.

I started my post-graduate work on potato in 1947 at the Indian Agriculture Research Institute (IARI), New Delhi. Growing up in Tamil Nadu, I had witnessed the damage to the potato crop by a disease called late blight (caused by Phytophthora infestans) in the Nilgiri Hills. Potato was a very important crop here, and its destruction led to considerable distress for the local people, as this coincided with World War II, when rice too was in short supply, due to the lack of imports from Burma (Myanmar). While many scientists were already working on wheat and rice, potato was at that time under-researched in India, perhaps because of its geographical concentration in the hills of southern India and the eastern Himalayas.

I continued my research on potato at the University of Wageningen, the Netherlands, in 1949. I learnt that during World War II, potato became the major food crop in Europe, leading to the abandonment of traditional crop rotations, and subsequently to the problem of resistance to the golden nematode in the polder lands. Potato is prone to a range of viruses, bacterial and fungal infections, and my work therefore focused on developing varietal lines resistant to pests and diseases.

I moved to Cambridge in 1950 and continued my PhD work on potato pests and diseases with Dr H WHoward. My work relied on inter-specific hybridisation, a technique that came to be increasingly used after the Irish potato famine of the 1840s. When I studied the question of why the Irish experienced such a serious epidemic pest, the late blight, I found the main reason to be the cultivation of a single variety. With no genetic variability, the potato became vulnerable to the rapid spread of disease. Fortunately, in Cambridge, there was a large collection of tuber-bearing potato (Solanum) species from Latin America, which provided valuable genes for developing lines of resistance to several serious stresses and diseases.

I published a paper in the American Potato Journal in 1951 on the importance of genetic diversity and variability, and this in fact, led to the US Department of Agriculture asking me to help them establish a potato collection at Sturgeon Bay, University of Wisconsin, Michigan. Here, one of the crosses I developed, between S. tuberosum and S. acaule, a species which grows at high altitudes in Peru, resulted in the frost-tolerant variety Alaska Frostless. Through my research, published in Biblographia Genetica, I demonstrated clearly that if we have enough genetic material in hand, we will be able to make new lines, resistant to disease or bearing specific characteristics.

Over a period of thousands of years, there have been mutations or changes to crops through a process of natural selection, that is, certain strains that are resistant to disease, survive. But once a plant becomes a crop, there is a process of human selection too that comes into play. So, potato breeders, for instance, selected strains of potato resistant to the late blight, after the Irish famine. For the coronavirus, part of the process of developing a vaccine is based on mapping the genetic traits of the virus. While nature conserves genes, human selection additionally takes account of quality, be if of food, or of human life itself.

The importance of genetic diversity and biodiversity cannot be emphasised enough in the context of food security. During the Bavarian war of succession in the late 18th century, there was a period called kartoffelkreig or the potato war. The potato crop was damaged by blight, and as the two armies had nothing to eat, while there were only minor skirmishes, thousands of soldiers died of starvation and disease. In Europe, this too emphasised the need for varietal diversity of potato, the main staple food. A single genetic strain, like the present COVID-19 pandemic, can lead to severe distress, in the absence of resistant strains.

Coming to the lessons in todays context, and for the future of food and agriculture in India, I again draw a parallel with the Irish potato famine. As the famine led to hunger and starvation, it also led to epidemics of infectious diseases. When people are starving, they are more prone to disease. On television, we find stories of migrants reporting that they might starve to death due to lack of food even if not due to the coronavirus. A basic problem we are confronting today is of inadequate food intake, especially for the poor and those already malnourished. This can affect immunity, but also longer-term nutrition and health.

There are two key lessons for food and nutrition security and agriculture more broadly. On the production side, the main moral lesson is to promote genetic heterogeneity. The late blight devastated the entire potato crop, leading to severe famine and loss of many lives. This implies the need to preserve and cultivate a range of varieties, be it of potato or other crops. In India, we are fortunate to have enough diversity of crops, so if one fails, there is always another crop.

However, at the present moment there is an issue of availability of suitable seed varieties, given that many of the standing crops have not been harvested. The government needs to ensure that seeds in adequate quantity and for a diversity of farming systems are made available to the farmer preparing now for the kharif sowing.

In the 1960s, I had started the first seed village in Jaunti in Delhi state. The idea was that the whole village produce seed to meet farmers demand, but also ensure farmers control over the varieties. Later known as participatory breeding, scientists from IARI and farmers worked together to develop characteristics there were desirable, both in terms of production yields, but equally taste and colour preferences. Farmers at that time preferred amber coloured wheat to red varieties such as Sonora, which we had acquired from Mexico, for making chapattis.

We experimented with vegetable seeds production villages in Tamil Nadu, in the early years of the M.S. Swaminathan Research Foundation (MSSRF) and while entire villages have not taken this up, there remain clusters of farmers who produce seeds for pulses, vegetables and so on. It is even more important now to support local production of seeds that ensure genetic variability. We need to specifically identify donor genes that can help develop varietal lines resistant to a range of pests, pathogens and weeds.

The other important lesson is in the field of post-harvest technology. In the present context of corona, and the national lockdown, farmers distress (especially for those producing horticultural crops) is intensified due to lack of post-harvest processing, storage, value addition and marketing mechanisms. The Amul model, supported by the National Dairy Development Board (NDDB), has demonstrated that even during the present COVID-19 crisis, the livelihoods of small farmers, in this case, milk producers, can be secured through collective action that ensures procurement, storage, transportation, value addition and marketing.

It is time that the National Horticultural Board is supported to play a proactive role similar to the NDDB. Even food crops are likely to get infected with fungi, aflatoxins and micro-toxins, in the absence of proper post-harvest storage and processing. In fact, following the Irish potato famine, in addition to potato collections to preserve genetic diversity, measures to protect both seed and food were put in place including modern storage systems.

Finally, during the Irish potato famine, people did not know what had happened, there was no information available till after the event. In India today, we have the advantage of excellent information and communication technology, which needs to be put to full use to reach the unreached with appropriate and timely information. There are several small initiatives towards this end. While the government machinery is providing good information on dealing with COVID-19, at the same time, we need to help our farmers and small producers deal with the threat of pest and disease in their farming systems too. For instance, close to a 100 farmers joined a plant clinic run by MSSRF, online for the first time.

The Green Revolution helped us move from a ship to mouth existence to a commitment to the right to food. Our food stocks need to be used to ensure the food security of the poor and hungry many of them farmers who have contributed to the building of this stock. This crisis is a time to recognise and strengthen our farming community women and men.

Citation:

Swaminathan, M.S. (1951) Notes on induced polyploids in the tuber-bearing solanum species and their crossability with s.tuberosum. American Potato Journal. 28: 472-482.

Swaminathan, M.S andHoward H.W (1953) The cytology and genetics of the potato (solanum tuberosum) and related species. Bibliographia Genetica. 16: 1-192.

M.S. Swaminathan is an eminent agricultural scientist, the winner of the World Food Prize, and was the Chairman of the National Commission on Farmers. Nitya Rao is Professor of Gender and Development at the School of International Development, University of East Anglia, the UK.

This article originally featured onMongabay-India.

Read the original:

COVID-19 and food security - Fitzwilliam College, University of Cambridge

Val Sheffield elected to the American Academy of Arts and Sciences – Iowa Now

Val Sheffield, the Roy J. Carver Chair in Molecular Genetics at the University of Iowa Roy J. and Lucille A. Carver College of Medicine, has been elected tothe 2020 class of the American Academy of Arts andSciences.

Sheffield was recognized for playing a key role in constructing human genetic maps and developing efficient disease-gene discovery approaches. This paved the way for the completion of the human genome project and significantly contributed to genetic discoveries in blinding eye diseases, obesity, hypertension, and neurological disorders, potentially leading to noveltherapies.

The American Academy of Arts and Sciences, founded in 1780 by John Adams and John Hancock, is both an honorary society that recognizes and celebrates the excellence of its members and an independent research center convening leaders from across disciplines, professions, and perspectives to address significant challenges. Elected members join with other experts in cross-disciplinary efforts to produce reflective, independent, and pragmatic studies that inform public policy and advance the publicgood.

This year, 276 new members were elected and include notable scientists, artists, scholars, and leaders in the public, nonprofit, and private sectors. Sheffield joins 58 other leaders in the medical sciences specialty. Academy members are nominated and elected by current members and chosen for excellence in their field and a record of continuedaccomplishment.

Sheffield is eager to contribute hisexpertise.

Genetic and genomic data are increasingly being integrated into the practice of medicine. With my expertise in human molecular and clinical genetics and genomics, Im hoping to be a useful resource to the academy, Sheffieldsays.

This is an incredible honor and well-deserved national recognition. We are extremely proud of Dr. Sheffield and his achievements, says Brooks Jackson, UI vice president for medical affairs and the Tyrone D. Artz Dean of the Carver College of Medicine.Given these turbulent times, it is especially gratifying to be able to celebrate hissuccess.

Sheffield joined the UI in in 1990 to perform research and practice clinical genetics in the Division of Medical Genetics for the UI Stead Family Department of Pediatrics. He has spent his entire career at Iowa, where he served as director of the Division of Medical Genetics for 22 years until stepping down in January 2020. He conducts scientific research related to human genetic diseases, however, he has recently converted a portion of his lab to join researchers across the world fighting the coronaviruspandemic.

Since the COVID-19 shutdown, I have switched some of my laboratory personnel to a COVID-19 project. We are trying to devise a simple method for collecting samples from patients for COVID-19 testing that doesnt require nasal swabs (in short supply) or use medical personnel to collect samples. The person being tested will self-collect the sample, thus saving on personnel and personal protective equipment. I am hoping to get FDA approval soon for this method so that it can be used to expand needed testing throughout Iowa, Sheffieldsays.

At the UI, Sheffield trains doctoral and medical students as a professor of pediatrics and a professor of ophthalmology and visual sciences. He also is an investigator for the UI Institute for Vision Research and practices medicine, caring for patients with human genetic disorders. He has co-authored more than 330 peer-reviewed scientific papers. He previously was an investigator for the Howard Hughes Medical Institute (HHMI), from 1998 to2016.

The members of the class of 2020 have excelled in laboratories and lecture halls, they have amazed on concert stages and in surgical suites, and they have led in board rooms and courtrooms, says academy President David W. Oxtoby. These new members are united by a place in history and by an opportunity to shape the future through the academys work to advance the publicgood.

Sheffield attended Brigham Young University, where he earned a bachelors degree in zoology and a masters degree in developmental biology. He received a doctoral degree in developmental biology and a medical degreewith honors from the University of Chicago. He was a resident in pediatrics and fellow in medical genetics at the University of California, SanFrancisco.

His research has been funded by the National Institutes of Health (NIH) for 29 consecutive years, as well as by the Roy J. Carver Charitable Trust. Sheffields honors include the E. Mead-Johnson Award for Pediatric Research and the Lewis Rudin Prize from the New York Academy of Science, and he is a member of the National Academy of Medicine. Sheffield is board certified by the American Board of Medical Genetics and Genomics in both clinical genetics and clinical moleculargenetics.

Sheffield joins the following UI faculty and administrators who havebeen elected members of the American Academy of Arts andSciences:

The rest is here:

Val Sheffield elected to the American Academy of Arts and Sciences - Iowa Now

DNA gives clues into risk of developing Alzheimer’s disease and other dementias – Alabama NewsCenter

Neurodegenerative diseases such as Alzheimers disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia can be devastating for patients and families, particularly in cases when symptoms show up in people younger than 65.

More than 5 million Americans are currently living with Alzheimers disease. Another 20,000-30,000 people have frontotemporal dementia and at least 16,000 have ALS. While scientists have some ideas about what causes these conditions, theres a lot of information they dont have, particularly about how a persons genome the suite of genetic material or DNA that theyre born with might affect disease onset.

Now, scientists at the HudsonAlpha Institute for Biotechnology, the University of California, San Francisco (UCSF) and the University of Alabama at Birmingham (UAB) have uncovered a gene that doubles the risk of becoming ill with one of these diseases.

This work would have been impossible without the grassroots support of local Huntsville donors, said Richard M. Myers, PhD, HudsonAlpha president and science director. Being able to do projects like this that address the underlying causes of multiple different neurodegenerative diseases could make a real difference in finding earlier diagnostics and new treatments.

The researchers gathered DNA samples from more than 1,100 people in an effort led by Jennifer Yokoyama, PhD, an assistant professor of neurology at the University of California, San Francisco. About half of these people were healthy, while the other half had Alzheimers disease, ALS or frontotemporal dementia. Then the scientists used a technique called whole-genome sequencing to learn what each individuals genetic code looks like.

With more than one thousand genetic codes in hand, the researchers used computer programs to comb through the sequences and find genetic variants, or things that were different. They determined that people with neurodegenerative diseases were more likely to have variants in a gene named TET2. They discovered this gene after analyzing both the parts of the genome that serve as a blueprint for making proteins, the molecules that do things in the bodys cells, and the parts of the genome that control when and where those proteins get made.

Then, the research team looked at DNA sequences from more than 32,000 healthy people and people with neurodegenerative diseases. They confirmed that the variants they saw in the first 1,100 genomes they looked at were also present in other people with Alzheimers disease, ALS and frontotemporal dementia more often than in healthy people.

Were excited that we did find a new genetic association here, said Nicholas Cochran, PhD, a senior scientist in the Myers Lab at HudsonAlpha.

You never know what genes might show up in a research project like this, but TET2 is exciting. This gene is the DNA blueprint for a protein called TET2, which has already been shown to have a role in maintaining the brains DNA. The researchers think the variants that they found that lead to a non-functional version of the protein might disrupt how the brain ages and contribute to the development of Alzheimers disease, ALS and frontotemporal dementia.

In addition to the generous support of local Huntsville donors to the HudsonAlpha Foundation Memory and Mobility Program, the work, which was recently published in The American Journal of Human Genetics, was funded by the Rainwater Charitable Foundation, the Daniel Foundation of Alabama, the Larry L. Hillblom Foundation, and the National Institutes of Health National Institute on Aging.

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlphas vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nations second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and includes more than 30 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

Here is the original post:

DNA gives clues into risk of developing Alzheimer's disease and other dementias - Alabama NewsCenter

Rare Gene Discovered That Nearly Doubles Risk of Developing a Neurodegenerative Disease – Clinical OMICs News

A multi-institutional team of researchers from the HudsonAlpha Institute for Biotechnology, the University of California, San Francisco (UCSF), and the University of Alabama at Birmingham (UAB), have identified a rare genetic variant that sigifnicantly incresases the risk of developing diseases like Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

Finding evidence for a risk factor that contributes to multiple neurodegenerative diseases is exciting, said Richard M. Myers, Ph.D., president and science director of HudsonAlpha, in a press release. We already know that these diseases share some pathologies. This work shows that the underlying causes of those pathologies may also be shared.

The teams research, Non-Coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases was published April 23 in The American Journal of Human Genetics. For their study, the investigators sequenced and analyzed whole genomes of more than 1,100 people of European descent 435 cases of early-onset Alzheimers disease (EOAD) and frontotemporal dementia (FTD) and 671 controls. They found that rare variation in the gene TET2 nearly doubled the risk of developing diseases like Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

The project wouldnt have been possible without extensive collaboration between institutions, said first author Nicholas Cochran, Ph.D., a senior scientist in the Myers Lab. You end up being able to find things that you cant find working alone.

Jennifer Yokoyama, Ph.D., an assistant professor of neurology at UCSF, collaborated with Cochran on technical details and also managed the projects sample collection, the majority of which were collected over decades at the UCSF Memory and Aging Centerand then sequenced and analyzed at HudsonAlpha.

Once they had the sequencing results, the researchers noticed that many of the patients had early-onset versions of neurodegenerative disease, suggesting there would be a genetic component of their illness. During genome analysis, the researchers looked at both coding and non-coding regions of the genome for DNA sequence variants, a strategy that allowed them to be more confident that any possible genes they discovered would be implicated in these diseases

Upon identifying TET2, the investigators then compared their findings with existing genetic data from more than 32,000 healthy people and people with neurodegenerative diseases. This data confirmed that variants in TET2, in both protein-coding and non-coding regions, were more likely to be present in the genomes of people with AD, ALS, or FTD than in people without these diseases.

Given well-defined changes in DNA methylation that occur during aging, rare variation in TET2 may confer risk for neurodegeneration by altering the homeostasis of key aging-related processes, the researchers wrote. Additionally, our study emphasizes the relevance of non-coding variation in genetic studies of complex disease.

Next steps for this continued research will focus on how changes in TET2 levels or function could contribute to aging and neurodegenerative disease.

More here:

Rare Gene Discovered That Nearly Doubles Risk of Developing a Neurodegenerative Disease - Clinical OMICs News

Progress in understanding the genetic basis of mental health – SFARI News

On May 6, 2020, Benjamin Neale will discuss progress in mapping genetic risk factors for autism, schizophrenia and bipolar disorder.

His talk is part of the Simons Foundation Autism Research lecture series.

The past decade has seen rapid progress in mapping genetic risk factors for autism, schizophrenia and bipolar disorder. In this talk, Benjamin Neale will review this progress, delving into how study designs and genetic variants are teaching us about different aspects of mental health. With that backdrop, he will then introduce the International Common Disease Alliance (ICDA), a nascent effort to bring the community together to tackle the challenge of moving from genetic maps to biological mechanisms and medicine. The ICDA has developed a set of recommendations for realizing the promise of human genetics to transform our understanding of and treatment for common disorders, such as autism.

Registration is required for this free event.Further instructions and access to join the webinar will be sent to all registrants upon sign up.

Benjamin Nealeis an associate professor in the Analytic and Translational Genetics Unit at Massachusetts General Hospital, where he directs the Genomics of Public Health Initiative. He is also an associate professor in medicine at Harvard Medical School and an institute member at the Broad Institute. Neale is strongly committed to gaining insights into the genetics of common, complex human diseases. Neale and Mark Daly, both of whom are associated with the Broad Institute and Massachusetts General Hospital, lead the ADHD Initiative. This collaborative effort focuses on genomic studies of attention deficit hyperactivity disorder (ADHD).

View post:

Progress in understanding the genetic basis of mental health - SFARI News

Coronavirus was widespread in UK at very start of pandemic, says genetics expert – Sky News

One of the world's leading human genetics experts has told Sky News that coronavirus was widespread in the UK at the very start of the pandemic and a lack of vigilance allowed the virus to take hold.

Dr Kari Stefansson is overseeing a massive project in Iceland to genetically sequence every positive case of COVID-19 in the country to find out how it mutates and spreads.

He spoke to Sky News at the headquarters of his company deCODE Genetics in Reykjavik, which houses a massive database of more than half the Icelandic population's genetic material.

Founded almost a quarter of a century ago, the samples are used to look into the genetic components of diseases. Now he's looking into COVID-19.

He says sequencing tells them where the cases come from.

"So the virus now has basically a barcode for every part of the world," he said.

"There is a collection of mutation that is relatively characteristic for Austria, another for Italy as well as Great Britain and for the west coast of the United States etc."

Prof Stefansson said that in the beginning, almost all of the cases came into Iceland from the Alps, from people who had been skiing in Austria and Italy.

The authorities responded by trying to contain the spread of infection from those high risk countries.

He added: "But as they were doing this, the virus was actually sneaking into the country with people from all kinds of other countries.

"And the most notable there is Great Britain. So it looks like the virus had a fairly wide spread in Great Britain very, very early in this epidemic."

:: Listen to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Prof Stefansson said the UK - and the USA - weren't vigilant enough from the start, pointing to Iceland's policy of mass testing.

Iceland has now tested a higher percentage of the population than any other nation. 45,000 tests have been carried out in a population of 360,000.

deCODE is working alongside the health service to take samples from as many people as possible - the sick as well as the seemingly healthy.

Dr Stefansson says that is the only way to discover the true spread of the disease in the community.

The policy has allowed Iceland to identify cases quickly and isolate carriers.

After it was suggested that it is easier for a small nation to test and bring the virus under control, he replied: "Yes, there may be fewer of us but countries like the United Kingdom and the United States have much, much more resources than we do.

"It is all just a question of using what you have. They weren't vigilant enough. They didn't react to this early enough.

"You know, the countries that taught us the methods that we are using, in doing this in a place like Iceland, they didn't use it themselves. And that is tragic."

As well as testing for COVID-19, deCODE is also taking blood from volunteers to test for antibodies to fight the virus.

And the company is examining whether there is a genetic component to coronavirus.

Dr Stefansson says it is curious how different people respond to the virus.

"There are those who describe this as a mild cold," he said.

"There are those who end up in the intensive care unit on a respirator. And there is everything in between.

"We know that women have less tendency to get infected than men. And if they get infected, they don't get as sick as men. What is it that generates this clinical diversity?"

That is the big question that needs answering, he says, and deCODE has already begun sharing its findings in the hope of finding an answer.

Follow this link:

Coronavirus was widespread in UK at very start of pandemic, says genetics expert - Sky News

This is how you do the genetics heritage filter on Instagram that everyone’s doing – The Tab

Rogue Instagram filters have been a saving grace right now as were all quickly running out of things to do. The newest one that most people are loving is the genetics heritage scanner filter. This filter scans you and makes you think its going to tell you what percentage of a certain nationality you are, but then actually morphs your face into a weird human/animal creature.

This filter merges surprise, ugly faces and animals all in one the perfect combination to guarantee a laugh every single time, without fail.Get involved, then get your mum involved, then (for some real comedy gold) send to your grandparents and get them to make one. Its a great time and this is how you do it.

Its a filter on Instagram that pretends to scan your face at first a load of different nationalities flick past (Welsh, French, Italian, etc) as well as a percentage. At this point, youll think its just boring and slightly problematic but then suddenly it lands on 85 per cent pangolin and morphs your face into a messed up (but hilarious) animal shape. Like so:

There are a lot of different animals you can get. We dont know exactly how many but weve seen crab, mole, rat, dog, pangolin, slug, limpet, llama, wasp and chameleon.

The official name for the filter is genetics scanner and it was created by iamcraiglewis2. If someone on your Insta uses it, youll see the name of the filter in the top left corner, you can then click on this and save it.

You can also search for the filter on your phone. If you go onto your camera on Insta, scroll right through all the filters at the bottom until you find the search icon. Then search genetics and it will come up, save it onto your phone and youve got hours of fun right there.

The reality stars with the highest percentage of fake Instagram followers

How to check if someones bought fake Instagram followers

Faked in Chelsea: How many fake Instagram followers the MIC cast have

Read the original:

This is how you do the genetics heritage filter on Instagram that everyone's doing - The Tab

MRC scientists elected Fellows of the Royal Society – Cambridge Network

As the UKs independent academy for science, the Royal Society seeks to promote excellence in science through its fellowships and foreign memberships. Each year, the Royal Society elects up to 52 new Fellows and up to 10 new Foreign Members, recognising scientists who have made substantial contributions to the improvement of knowledge in the sciences.

Professor Gordon Brown, Director of the MRC Centre for Medical Mycology at the University of Exeter, is an international leader in the fields of innate immunity and medical mycology. Professor Browns work is recognised for significantly advancing our understanding of host-pathogen interactions, and his research has helped to bring mycology into the mainstream interest of the immunology community.

Dr Francois Guillemot is a Senior Group Leader focused on molecular neurobiology at the Francis Crick Institute. Dr Guillemots Group aims to learn exactly how cells of the nervous system form, where and at what stage in development, in order to generate new ideas for therapies to treat brain disorders.

Professor Andrew Jackson is a clinical geneticist and Programme Leader at the MRC Human Genetics Unit at the University of Edinburgh and is the Deputy Chair of the MRC Molecular and Cellular Medicine Board. Professor Jacksons research has focussed on the identification of genes for inherited neurological disorders and in defining the functional role of the proteins they encode, in particular human disease genes acting in growth and inflammation, involved in fundamental cellular processes.

Dr William Schafer is a Group Leader in the Division of Neurobiology at the MRC Laboratory of Molecular Biology. Dr Schafers research addresses basic questions about how ion channels and signaling molecules function in the context of neural circuitry to produce behaviour and he is recognised for being instrumental in developing optical approaches for measuring neural activity, and applying these methods to investigate how individual genes affect the activities of neurons in defined neural circuits, and how this impacts behaviour.

Visit the Royal Society website for a full list of the Fellows and Foreign Members elected in 2020.

Originally posted here:

MRC scientists elected Fellows of the Royal Society - Cambridge Network

COVID-19 vaccine in Ireland could take a year and a half – IrishCentral

"Vaccines take time to develop years, if not decades. But, due to the urgency of the pandemic, the timetable is being shortened."Getty

A COVID-19 vaccine may not be available in Ireland for another year and a half, experts have warned.

The Irish Pharmaceutical Healthcare Association (IPHA) noted that while progress is being made, it could be as late as October 2021 before a vaccine is developed, tested, approved, and manufactured.

The IPHA said, Vaccines take time to develop years, if not decades. But, due to the urgency of the pandemic, the timetable is being shortened.

But scientists know that there can be no short-cuts on the testing needed to ensure a vaccine, or a treatment, is safe and effective.

Read more:Irish scientist leads Oxford COVID-19 vaccine drive considered most promising

Several medicines to treat the virus are already in various stages of development while some are even in the late phase of clinical trials.

Ultimately the IPHA said a vaccine is the only way to effectively protect the worlds population against any further waves of the deadly coronavirus.

Ireland, like many nations around the world, is contributing to the development of a vaccine or treatment, with figures in the pharmaceutical industry working in partnership with government officials, academics, health authorities, patient advocacy groups, and charities in a coordinated response.

Jon Barbour, director of Medical Affairs with pharmaceutical giant GSK Ireland, said, The great challenge in the Covid-19 pandemic is to develop an effective vaccine quickly.

The good news is that this is the first time in history that there has been such a concerted global effort and collaboration between pharmaceutical companies and research organizations to find a specific vaccine.

According to the latest data from the World Health Organization, there are three vaccine candidates in clinical evaluation and at least 67 vaccine candidates in preclinical evaluation globally.

GSK is currently collaborating with fellow pharmaceutical firm Sanofi on an adjuvanted Covid-19 vaccine designed to promote a better immune response to the virus.

Read more:New drug effective against COVID-19 clinical trial shows

Adjuvants can also reduce the amount of a virus required to produce a vaccine.

However, Barbour warned that vaccine development is a lengthy, complex process and there are no shortcuts.

Once a vaccine has come through the clinical trial process, the next challenge will be scaling up manufacturing to produce millions of doses which will require a partnership approach between pharmaceutical manufacturers that have the expertise and resources to produce vaccines to meet global need, he said.

Despite his calls for patience, several other potential vaccines are already heading towards clinical trials.

Johnson & Johnson is to begin human clinical trials on a vaccine this September, with a view to have a several batches available for emergency uses as early as next year.

Pfizer is also Germanys BioNTech to co-develop a potential vaccine while the British American Tobacco Company is also working on a possible solution.

The most advanced effort is taking place at the University of Oxford, where the first human trials for a Covid-19 vaccine began last week.

Professor Adrian Hill, an Irish scientist who has worked on Ebola and malaria vaccines, is heading up the Oxford University Covid-19 vaccine effort which The New York Times says is currently the leader in the search for a workable vaccine.

In the worldwide race for a vaccine to stop the coronavirus, the laboratory sprinting fastest is at Oxford University, the Times reports.

Hill and Oxford researchers had already been working on coronavirus type vaccines and just very recently monkey trials showed the Oxford vaccine protected the animals from Covid-19.

Dublin-born Hill 61, head of the Jenner Institute in Oxford and Professor of Human Genetics developed a fascination with malaria and other tropical diseases as a medical student in Dublin in the early 1980s when he visited an uncle who was a priest working in a hospital during the civil war in what is now Zimbabwe.

Read more:Irish create 3D printed ventilators to fight COVID-19 pandemic

"Vaccines take time to develop years, if not decades. But, due to the urgency of the pandemic, the timetable is being shortened."Getty

Here is the original post:

COVID-19 vaccine in Ireland could take a year and a half - IrishCentral

Humans: are we the most effective vector of disease? – BugBitten – BMC Blogs Network

Over one-seventh of the world's population moved within the last year. Migration is only expected to increase in the coming years. What is important to understand about these populations so that we can improve the health of all?

Christina Faust 1 May 2020

One billion people were on the move or have moved in the last year. The majority of this movement occurs within countries, but people are also moving across international boundaries. The scale of people moving raises the question: are we the most prevalent vectors of disease?

Restrictions to limit travel for essential purposes only has slowed down the movement of people within countries and between countries in an effort to curb the spread of COVID-19 and protect those most vulnerable to the pandemic. It is easy to see how human movement plays a role in the movement of new pathogens and historical movement has introduced malaria, leprosy, and smallpox across the globe. But what about diseases that are endemic?

Research has focused on emerging infections, but work also been done to show how human movement affects important viruses, such as measles and yellow fever virus. In this blog well focus on the increasing capacity to understand how human movement affects parasitic diseases, when it is crucial to understand human movement, and how lessons can be applied to improve control of endemic disease. We will use extensive work on malaria to illustrate how human movement affects transmission, particularly close to elimination targets, and some new theoretical work on how these tools and concepts can be used in neglected tropical diseases, namely soil-transmitted helminths.

The reasons for movement are many: business, tourisms, labour migration (including seasonal work), forced migration, climate change refugees, and even human trafficking. The drivers of movement are complex and dynamic, but are essential to understand for the sustainable control of many infectious diseases.

The majority of research on human movement and parasitic diseases has been conducted on malaria. A previous post discussed a recent paper that investigated the role of mosquito movement in the long- distance dispersal of vectors and potentially disease. However, human movement leads to introduction of malaria to new places and has been shown to increase risk of infection with zoonotic malaria. For countries aiming for elimination, it is important to prevent introduction of new cases and differentiate this from ongoing transmission within resident populations. For example, astudy examined this question across Southeast Asia and demonstrated that some malaria parasite transmission networks are isolated, suggesting that human movement is not that important in these areas. However many other parasite transmission networks occurred on international scales, suggesting treating migrants and/or travelers will be essential. Within Bangladesh, another study combined genetics of the parasites with surveys and mobile phone calling data to understand where transmission was occurring within a heterogenous region with large areas of forests but also cities. Combining these three datasets, they were able to show that parasites were being spread over large distances through human movement and that the clinical cases alone could not be used to design interventions in that part of the country. Movement between rural and urban environments, through human movement (for work, education, family visits, etc) has also been shown to be important for tuberculosis and other diseases.

Although there is not empirical data, yet, for the role of human movement in the spread and transmission of soil-transmitted helminths, some recent work has modelled the impact of movement on control of STHs. As countries move from elimination of STH as a public health problem to elimination of the diseases, the authors show that the role of human migration will become increasingly important. If a location is near achieving elimination, migration of infected humans into the control area can lead to a variety of outcomes, depending on how many are infected and how often they are moving in/out. Therefore, in places that have achieved control of a disease, it will be important to understand the role of human movement in subsequent infections.

Efforts are underway to help map population movement, but oftentimes the most vulnerable are left out of these metrics. Migration, rather than a challenge to health systems, can be an opportunity for improving health of migrants and residents. There are many organizations working to improve access to health services and in particular improve outbreak response. As more and more people move around in this world, it will be important to address health of migrants to improve health for all.

Continued here:

Humans: are we the most effective vector of disease? - BugBitten - BMC Blogs Network

Parkinson’s discovery implicates "second brain" in the gut – New Atlas

A growing body of evidence is forging a stronger and stronger connection between the onset of Parkinsons disease and the gut. Scientists at Karolinska Institutet in Sweden and the University of North Carolina at Chapel Hill have thrown further weight behind this theory, with an investigation of cellular behavior in the nervous system of the digestive system revealing possible tell-tale signs at the earliest stages of the disease.

The notion that Parkinsons disease could get its start in the gut has been around for some time, but in recent years we are seeing some compelling research that suggests our bellies may well play an important role in its onset. The disease is characterized by the cell death of neurons that secrete dopamine in the brain, which drives the motor impairments and other common symptoms of the illness.

What causes the demise of these neurons is not known for certain, but a leading hypothesis is that it is caused by aggregations of misfolded proteins known as Lewy bodies. An animal study last year produced the best evidence to date that these toxic protein clumps first form in the gut and move upward to the brain via the vagus nerve.

This new research hints at the role the enteric nervous system, as the regulator of digestive system, could play in these processes. Made up of a hundreds of millions of neurons, the bodys largest collection outside the brain, the enteric nervous system can operate independently of the central nervous system and for this reason is sometimes referred to as the second brain.

The authors of the new research studied gene expression in mice in combination with human genetics to systematically identify cell types that underly certain brain disorders. They then analyzed brain tissue taken from both healthy subjects and sufferers of Parkinsons, taken at different stages of the disease. This revealed alterations in enteric neurons, even at the earliest stages of disease progression, the scientists write.

"As expected, we found that dopaminergic neurons were associated with Parkinson's disease, says senior author Patrick Sullivan. More surprisingly, we found that enteric neurons also seem to play an important role in the disorder, supporting the hypothesis that Parkinson's disease starts in the gut.

The teams research also produced another useful insight. By looking at these brain tissue samples taken at different points in disease progression, they found that important support cells in the brain called oligodendrocytes were impacted early on, even before the loss of the dopamine-producing neurons.

These results suggest that oligodendrocyte could be an attractive target for therapeutic interventions as they appear to be affected before dopaminergic neurons, says the Karolinska Institutets Julien Bryois, senior author of the study.

The research was published in the journal Nature Genetics.

Source: Karolinska Institutet via EurekAlert, University of North Carolina at Chapel Hill

Read more from the original source:

Parkinson's discovery implicates "second brain" in the gut - New Atlas

Could genetics explain why some COVID-19 patients fare worse than others? – Live Science

Certain genetic differences might separate people who fall severely ill with COVID-19 from those who contract the infection but hardly develop a cough, a new preliminary study suggests.

The research is still in its early days, though, experts say.

The immune system can react to viruses thanks, in part, to specific genes that help cells spot unfamiliar bugs when they enter the body. The genes, known as human leukocyte antigen (HLA) genes, contain instructions to build proteins that bind to bits of a pathogen; those proteins serve as warning flags to alert immune cells. The immune cells, once trained to recognize these bits, jumpstart the process of building antibodies to target and destroy the invasive germ.

Within each individual, HLA genes code for three different classes of proteins; in other words, HLAs come in a variety of flavors, and depending on which HLAs you have, your body may be better or worse equipped to fight off certain germs including SARS-CoV-2, the virus that causes COVID-19.

In a new study, published April 17 in the Journal of Virology, researchers used computer models to predict which combination of HLAs might be best at binding SARS-CoV-2, and which might be worst.

If certain HLAs can bind well to a large proportion of the virus's proteins, "we expect there to be a more protective immune response," authors Abhinav Nellore and Dr. Reid Thompson, who lead a computational biology research group at the Oregon Health and Science University, told Live Science in an email. A better bind means that the viral proteins are more likely to be presented to immune cells and prompt the production of specific antibodies, the authors said.

"If the interaction is not stable, you will not have a proper [immune] response," said Dr. Shokrollah Elahi, an associate professor in the Department of Dentistry and adjunct associate professor in the Department of Medical Microbiology and Immunology at the University of Alberta, who was not involved in the study.

Related: 10 deadly diseases that hopped across species

But a stable bond, alone, does not guarantee the best immune response, Elahi added. If an HLA binds a viral protein that happens to be critical for the germ to replicate and survive, the subsequent antibody activity will likely target the virus more effectively than that prompted by a less important protein, Elahi said.

"This is an issue we did not address in our analysis," the authors noted. Instead, the team focused on predicting how well different HLA types could bind to bits of SARS-CoV-2. Their analysis identified six HLA types with a high capacity to bind different SARS-CoV-2 protein sequences, and three with a low capacity to do so. Specifically, a HLA type known as HLA-B*46:01 had the lowest predicted capacity to bind to bits of SARS-CoV-2.

The same HLA type cropped up in a 2003 study published in the journal BMC Medical Genetics, which assessed patients infected with SARS-CoV, a closely related coronavirus that caused an outbreak of severe acute respiratory syndrome in the early 2000s. The study found that, in a group of patients of Asian descent, the presence of HLA-B*46:01 was associated with severe cases of the infection. In their paper, the research group noted that more clinical data would be needed to confirm the connection and the same goes for the new study of SARS-CoV-2, Nellore and Thompson said.

"The most substantial limitation of our study is that this was conducted entirely on a computer and did not involve clinical data from COVID-19 patients," the authors said. "Unless and until the findings we present here are clinically validated, they should not be employed for any clinical purposes," they added.

"In the body, we have so many things interacting," Elahi said. HLAs represent just one piece of a large, intricate puzzle that comprises the human immune system, he said. To better understand the variety of immune responses to COVID-19, Elahi and his research group aim to assess markers of immune system activity in infected patients and also catalog the ratio of immune cell types present in their bodies. While taking age, sex and other demographic factors into account, these so-called immunological profiles could help pinpoint when and why the illness takes a turn in some patients.

The clinical data could be assessed in parallel with genetic data gathered from the same patients, Elahi added. Similarly, Nellore and Thompson said that "COVID-19 testing should be paired with HLA typing, wherever [and] whenever possible," to help determine how different HLA types relate to symptom severity, if at all. Partnerships with genetic testing companies, biobanks and organ transplant registries could also offer opportunities to study HLA types in larger populations of people, they said.

"We cannot in good conscience predict at this point who will be more or less susceptible to the virus because we have not analyzed any clinical outcomes data with respect to HLA type to know that any of our predictions are valid," the authors said. If future studies support the notion that some HLA genes protect people from the virus, while others place patients at greater risk, those in the latter group could be first in line for vaccination, they added.

"In addition to prioritizing vaccinating the elderly or those with preexisting conditions, one could prioritize vaccinating people with HLA genotypes that suggest the SARS-CoV-2 virus is more likely to give them worse symptoms."

The authors went on to analyze how well HLAs can bind SARS-CoV-2 as compared with other coronaviruses, such as those that cause the common cold and infect humans often. They identified several viral bits shared between SARS-CoV-2 and at least one of these common viruses, suggesting exposure to one germ could somewhat protect the body against the other.

"If someone was previously exposed to a more common coronavirus and had the right HLA types ... then it is theoretically possible that they could also generate an earlier immune response against the novel SARS-CoV-2," the authors said. On the other hand, exposure to a similar virus could leave the body ill-equipped to fight off the new one, if, for instance, "the body is using an old set of tools that aren't ideally suited to address the new problem," the authors said.

Originally published on Live Science.

Read the original here:

Could genetics explain why some COVID-19 patients fare worse than others? - Live Science

Human Genetics Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

GE

Global Human Genetics Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=177432&utm_source=LHN&utm_medium=888

Human Genetics Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Human Genetics industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Human Genetics industry.

-> Furthermore, we will help you to identify any crucial trends to predict Human Genetics market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Human Genetics market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=177432&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Human Genetics market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Human Genetics market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Human Genetics Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Human Genetics Market Size, Human Genetics Market Growth, Human Genetics Market Forecast, Human Genetics Market Analysis

Our Trending Reports

Automotive Automatic Transmission Control Unit Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive Biometric Vehicle Access System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:

Human Genetics Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

American Academy of Arts & Sciences Elects UVM’s Wallace to Its Membership – UVM News

The American Academy of Arts & Sciences has announced the election of University of Vermont Professor of Microbiology and Molecular Genetics Emerita Susan Wallace to its membership in recognition of her status as a world leader in the sciences. Wallace joins 275 new members elected on April 23, 202

Academy members represent innovative thinkers in every field and profession, including more than 250 Nobel and Pulitzer Prize winners.

Wallace, who served as chair of UVMs Department of Microbiology and Molecular Genetics for 30 years before her retirement in 2018, played a significant role in providing a much greater understanding of the fundamental DNA repair mechanisms involved in the development of cancer, as well as the effects of radiation damage to the genome. More recently, her research, which was supported by more than 47 years of consistent National Institutes of Health funding, explored a potential link between certain DNA repair protein variants in the human population and an increase in the risk for some types of cancer. She is the author of more than 200 biomedical journal articles and trained many successful graduate students and postdoctoral fellows during her career at UVM.

It is both an honor and a privilege for me to be chosen as a member of this distinguished group, said Wallace. I am looking forward to working together with Academy members to keep basic science research at the forefront of our Nations goals.

Named a UVM University Distinguished Professor in 2011, Wallace was one of only a few scholars who chaired a department across two colleges the Larner College of Medicine and the College of Agriculture and Life Sciences. Her many honors include election as a Fellow of the American Association for the Advancement of Science; the Harvard School of Public Healths John B. Little Award for Outstanding Contributions to Molecular Radiobiology; the Environmental Mutagenesis and Genomics Society Award for Fundamental Studies on Repair of DNA Damage Caused by Environmental Agents and for her Exemplary Leadership; and the Failla Award from the Radiation Research Society. Her leadership roles at UVM included service as the director of the Department of Energy Vermont EPSCoR Program, director of the Vermont Cancer Center (now UVM Cancer Center) Genome Stability and Expression Program, director of the Cancer Biology Training Program, and associate director for basic and translational science in the Cancer Center.

The members of the class of 2020 have excelled in laboratories and lecture halls, they have amazed on concert stages and in surgical suites, and they have led in board rooms and courtrooms, said Academy President David W. Oxtoby in the organizations announcement. With todays election announcement, these new members are united by a place in history and by an opportunity to shape the future through the Academys work to advance the public good.

Election to the American Academy of Arts & Sciences is a signal accomplishment for a scholar, said Suresh Garimella, president of the University of Vermont. It is a fitting tribute to Dr. Wallace who, through a long and distinguished career, has made significant contributions to our understanding of how cancer develops and factors that increase its risk. We are very proud of her at UVM and offer our heartiest congratulations.

Over her long career here in Burlington, Dr. Wallace distinguished herself as an exceptional leader, mentor and scientist, noted Richard Page, dean of the Larner College of Medicine. Her fundamental discoveries have advanced our understanding of the role DNA repair plays in development of cancer and the effect of radiation on the genome. Our entire Larner community congratulates Dr. Wallace, and we celebrate this well-deserved honor with her.

This recognition is a testament to Dr. Wallace's contributions to science and leadership as a female pioneer in the field of genetics, said Jean Harvey, dean of the College of Agriculture and Life Sciences.It has been a pleasure and privilege to have had the opportunity to work with Dr. Wallace over the years. On behalf of the College of Agriculture & Life Sciences, we join in congratulating Dr. Wallace on this significant achievement.

Other UVM faculty with membership in the American Academy of Arts & Sciences include Professor of Biology Emeritus Bernd Heinrich, Marsh Professor-at-Large Madeleine M. Kunin, and Professor of Molecular Physiology and Biophysics Emerita Susan Lowey. In addition, UVM has among its ranks two members of the National Academies, including UVM Distinguished Professor and Chair of Pharmacology Mark Nelson, a member of the National Academy of Sciences, and University Distinguished Professor and Professor of Engineering George Pinder, a member of the National Academy of Engineering.

The American Academy was founded in 1780, during the American Revolution, by John Adams, John Hancock, and 60 other scholar-patriots who understood that a new republic would require institutions able to gather knowledge and advance learning in service to the public good. The Academy is both an honorary society that recognizes and celebrates the excellence of its members and an independent research center, convening leaders from across disciplines, professions, and perspectives to address significant challenges.

About the University of Vermont

Since 1791, the University of Vermont has worked to move humankind forward. Today, UVM is a top 100 research university of a perfect size, large enough to offer a breadth of ideas, resources, and opportunities, yet intimate enough to enable close faculty-student mentorship across all levels of study, from bachelors to M.D. and Ph.D. programs. One of the first land grant universities in the nation, UVM advances Vermontand the broader societythrough the discovery and application of new knowledge. And by drawing on its location, it provides unique opportunities to explore, challenge ideas, and take on the most pressing issues of our time.

View original post here:

American Academy of Arts & Sciences Elects UVM's Wallace to Its Membership - UVM News

The PBS documentary The Gene showcases genetics promise and pitfalls – Science News

The genetic code to alllife on Earth, both simple and complex, comes down to four basic letters: A, C,T and G.

Untangling the role thatthese letters play in lifes blueprint has allowed scientists to understandwhat makes everything from bacteria to people the way they are. But as researchershave learned more, they have also sought ways to tinker with this blueprint,bringing ethical dilemmas into the spotlight. The Gene, a two-part PBS documentary from executive producer Ken Burnsairing April 7 and 14, explores the benefits and risks that come withdeciphering lifes code.

The film begins with oneof those ethical challenges. The opening moments describe how biophysicist HeJiankui used the gene-editing tool CRISPR/Cas9 to alter the embryos of twin girls who were born in China in 2018 (SN: 12/17/18). Worldwide, criticscondemned the move, claiming it was irresponsible to change the girls DNA, asexperts dont yet fully understand the consequences.

This moment heraldedthe arrival of a new era, narrator David Costabile says. An era in whichhumans are no longer at the mercy of their genes, but can control and evenchange them.

Headlines and summaries of the latest Science News articles, delivered to your inbox

The story sets the stagefor a prominent theme throughout the documentary: While genetics holdsincredible potential to improve the lives of people with genetic diseases,there are always those who will push science to its ethical limits. But thedriving force in the film is the inquisitive nature of the scientistsdetermined to uncover what makes us human.

The Gene, based on the book of the same name by Siddhartha Mukherjee (SN:12/18/16), one of the documentarys executive producers, highlights many ofthe most famous discoveries in genetics. The film chronicles Gregor Mendels classicpea experiments describing inheritance and how experts ultimately revealed inthe 1940s that DNA a so-called stupid molecule composed of just four chemicalbases, adenine (A), thymine (T),cytosine (C) and guanine (G) is responsible for storing geneticinformation. Historical footage, inBurns typical style, brings to life stories describing the discovery of DNAshelical structure in the 1950s and the success of the Human Genome Project indecoding the human genetic blueprint in 2003.

The film also touches ona few of the ethical violations that came from these discoveries. The eugenicsmovement in both Nazi Germany and the United States in the early 20th century aswell as the story of the first person to die in a clinical trial for genetherapy, in 1999, cast a morbid shadow on the narrative.

Interwoven into thistimeline are personal stories from people who suffer from genetic diseases.These vignettes help viewers grasp the hope new advances can give patients asexperts continue to wrangle with DNA in efforts to make those cures.

In the documentarysfirst installment, which focuses on the early days of genetics, viewers meet a family whose daughter is grappling with arare genetic mutation that causes her nerve cells to die. The family searchesfor a cure alongside geneticist Wendy Chung of Columbia University. The secondpart follows efforts to master the human genome and focuses on AudreyWinkelsas, a molecular biologist at the National Institutes of Health studyingspinal muscular atrophy, a disease she herself has, and a family fighting tosave their son from a severe form of the condition.

For science-interested viewers, the documentary does not disappoint. The Gene covers what seems to be every angle of genetics history from the ancient belief that sperm absorbed mystical vapors to pass traits down to offspring to the discovery of DNAs structure to modern gene editing. But the stories of the scientists and patients invested in overcoming diseases like Huntingtons and cancer make the film all the more captivating.

Continued here:

The PBS documentary The Gene showcases genetics promise and pitfalls - Science News

Few clinical trials are done in Africa: COVID-19 shows why this urgently needs to change – The Conversation Africa

The World Health Organisation (WHO), in its quest to find efficacious therapies to treat COVID-19, plans to conduct a multi-arm, multi-country clinical trial. The trials have yet to begin, but ten countries have already signed up. Only one of them, South Africa, is on the African continent.

Of course, the WHO isnt the only organisation trying to find treatments or even a vaccine for COVID-19. The United States National Institutes of Health maintains an online platform that lists all registered, ongoing clinical trials globally. On March 26, a quick search of the platform using the term coronavirus revealed 157 ongoing trials; 87 of these involve either a drug or a vaccine, while the rest are behavioural studies. Only three are registered in Africa all of them in Egypt.

This low representation of African countries in clinical trials is not unusual. Poor visibility of existing sites, limited infrastructure and unpredictable clinical trial regulatory timelines are some of the key issues hindering investments in this area.

Africas virtual absence from the clinical trials map is a big problem. The continent displays an incredible amount of genetic diversity. If this diversity is not well represented in clinical trials, the trial findings cannot be generalised to large populations.

The same goes for the outcomes of the COVID-19 studies. They too may not be relevant for people in African countries unless conducted locally. This is because responses to drugs or vaccines are complicated and can be influenced by, among other things, human genetics: different people will respond differently to different drugs and vaccines.

More countries on the African continent must urgently get involved in clinical trials so that the data collected will accurately represent the continent at a genetic level.

Time is of the essence. The usual approach, of developing site or country specific protocols, wont work. Instead, African governments need to look at ways to harmonise the response towards COVID-19 across the continent. Now, more than ever, African countries need to work together.

Africa does have clinical trial infrastructure and capabilities. But the resources remain unevenly distributed. The vast majority are in Egypt and South Africa. Thats because these countries have invested more heavily in research and development than others on the continent.

Traditionally, clinical trials are conducted at centres of excellence, which are sites that have the appropriate infrastructure and human skills necessary to conduct good quality trials. These can be located at a single university or research organisation, or work can be split between a few locations. But setting up these centres requires significant time and financial investment. Most that I am aware of on the continent have developed over the years with heavy support from external partners or sponsors. In many cases, African governments have not been involved in these efforts.

Once such centres are set up, the hard work continues to maintain these centres and to ensure theyre able to attract clinical trial sponsors. They require continuous funding, the establishment of proper institutional governance and the creation of trusted, consistent networks.

Usually African scientists leading clinical trial sites can apply for funding to conduct a trial; if the site is well known the scientists may be approached by a sponsor such as a pharmaceutical company interested in conducting a trial.

Clearly this approach takes time and usually benefits well-known sites or triallists. So what alternatives are available in the face of an epidemic thats moving as fast as COVID-19?

Key stakeholders should work together to expedite the rollout of trials in different countries. This would include inter-country collaborations such as working with different governments and scientists in co-designing trials; and providing harmonised guidelines on patient management, sample collection and tracking and sharing results in real time.

African governments, meanwhile, should provide additional funding to clinical research institutions and clinical trial sites. This would allow the sites to pull resources together and rapidly enrol patients to answer various research questions.

Because of the uneven distribution of skills and resources the continent should also adopt a hub-and-spoke model in its efforts. This would involve countries that dont have much capacity being able to ship samples easily across borders for analysis in a centralised well-equipped laboratory, which then feeds back data to the country of sample origin.

Governments should also form a task force to quickly engage with key pharmaceutical companies with drug candidates for COVID-19. This team should establish the companies appetite for collaborations in conducting relevant trials on the continent.

Through all of this, it is necessary for stakeholders to identify and address key ethical issues that may arise. Ethics should not be compromised by haste.

Every countrys epidemic preparedness kit should contain funds set aside for clinical trials during epidemics or pandemics.

This would require governments on the continent to evaluate their role and level of investment in the general area of clinical trials. This will augment the quality and quantity of clinical trials in the face of the constant challenge of emerging and re-emerging infectious diseases as well as a steady rise in non-communicable diseases.

On top of this, clinical trial centres, clinical research institutions and clinical triallists on the continent should strive to increase their visibility in the global space. This will make them easy to find in times of crisis, and enhance both south-south and north-south collaborations.

The African Academy of Sciences is currently building an online platform to facilitate this visibility and encourage greater collaboration.

Read more:

Few clinical trials are done in Africa: COVID-19 shows why this urgently needs to change - The Conversation Africa